{"id":36260,"date":"2013-04-22T16:25:03","date_gmt":"2013-04-22T20:25:03","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&p=36260"},"modified":"2013-04-22T16:26:11","modified_gmt":"2013-04-22T20:26:11","slug":"actelion-executive-to-head-american-college-of-cardiology","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2013\/04\/22\/actelion-executive-to-head-american-college-of-cardiology\/","title":{"rendered":"Actelion Executive to Head American College of Cardiology"},"content":{"rendered":"

Shalom “Shal” Jacobovitz will be the new chief executive officer of the American College of Cardiology, the ACC announced today. Jacobovitz is currently the president of the U.S. division of\u00a0Actelion\u00a0Pharmaceuticals, best known for its pulmonary hypertension drugs.<\/p>\n

\"Shalom<\/a>

Shalom “Shal” Jacobovitz<\/p><\/div>\n

Jacobovitz worked at Hoffmann La Roche, Abbott\u00a0Canada, Nordic Labs, and Marion Merrill Dow before joining\u00a0Actelion. \u00a0He joins the college after a year-long search that was initiated following\u00a0the sudden departure<\/a>\u00a0of the previous ACC CEO, Jack Lewin.<\/p>\n

\u201cShal has a track record that demonstrates he is the right person to lead a strong organization like the ACC and to take it to the next level at a time when health care is undergoing massive changes,\u201d said ACC President John Gordon Harold, in an ACC press release<\/a>. \u201cHe is an innovative and proven leader as well as a successful mentor and team builder. Shal brings a unique perspective at a time when the College is ramping up to meet the evolving needs of cardiovascular professionals domestically and around the globe.\u201d<\/p>\n

I asked Harold to comment on the issue of a pharmaceutical executive serving as the CEO of the ACC:<\/p>\n

The ACC has long been a leader in transparency and ensuring positive appropriate relationships with industry. Shal Jacobovitz and the ACC are committed to full transparency. Shal has voluntarily divested himself entirely of all personal investments in the pharmaceutical and medical device industries that could be perceived as a conflict of interest. It was never an issue.<\/p>\n

As the landscape evolves for physicians, medical professionals, payers, hospitals, and patients we wanted a CEO with the new approaches, perspectives, and skills that Mr. Jacobovitz possesses. He brings a wealth of experience in leading organizations during times of rapid change and in building strong, high-functioning teams to address these changes.”<\/p><\/blockquote>\n

\u201cIt is a privilege for me to join the ACC,\u201d Jacobovitz said in the ACC press release. \u201cThe College is a thriving medical professional society that is well positioned to be at the center of rapid changes in health care. I look forward to working with the ACC\u2019s dedicated professional staff and member leaders to build on the College\u2019s legacy of leadership in quality improvement, patient-centered care, clinical education and practice excellence.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

Shalom “Shal” Jacobovitz will be the new chief executive officer of the American College of Cardiology, the ACC announced today. Jacobovitz is currently the president of the U.S. division of\u00a0Actelion\u00a0Pharmaceuticals, best known for its pulmonary hypertension drugs. Jacobovitz worked at Hoffmann La Roche, Abbott\u00a0Canada, Nordic Labs, and Marion Merrill Dow before joining\u00a0Actelion. \u00a0He joins the […]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1776,1206],"class_list":["post-36260","post","type-post","status-publish","format-standard","hentry","category-general","tag-actelion","tag-american-college-of-cardiology"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/36260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=36260"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/36260\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=36260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=36260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=36260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}